Knowledge Base Wiki

Search for LIMS content across all our Wiki Knowledge Bases.

Type a search term to find related articles by LIMS subject matter experts gathered from the most trusted and dynamic collaboration tools in the laboratory informatics industry.

Edit links
Eldelumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCXCL10/IP-10
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6502H10024N1736O2026S48
Molar mass146468.72 g·mol−1

Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10)[2][1] designed for the treatment of Crohn's disease and ulcerative colitis.[3]

This drug was developed by Bristol-Myers Squibb and Medarex.[4]

References

  1. ^ a b Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, et al. (April 2016). "Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study". Journal of Crohn's & Colitis. 10 (4): 418–28. doi:10.1093/ecco-jcc/jjv224. PMC 4946756. PMID 26721935.
  2. ^ a b "Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs". www.creativebiolabs.net. Retrieved 2017-03-24.
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
  4. ^ "Eldelumab". AdisInsight. Springer Nature Switzerland AG.
source: https://en.wikipedia.org/wiki/Eldelumab